Testing a new immune-boosting cancer treatment alone or combined with another drug

Plain-English translation of NCT03972657 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called that works by boosting your immune system to fight cancer. Researchers want to find out if this treatment is safe and effective when given on its own, or paired with another immune-boosting drug called . The study includes two phases: first, doctors will find the right dose, and then they'll test how well the treatment works at shrinking tumors.

Advanced prostate cancer and kidney cancer can be hard to treat, especially after other therapies have stopped working. This medication uses a new approach to help your own immune system recognize and destroy cancer cells, offering hope for patients who have limited options.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic castration-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone therapy) or advanced clear-cell kidney cancer
you have already received at least two other systemic cancer treatments and they are no longer controlling your cancer
for prostate cancer specifically, you have received a second-generation anti-androgen therapy and a lutetium-based radiotherapy targeting PSMA
you have measurable tumors that can be tracked by imaging scans
you are willing to receive the study medication by infusion and attend regular clinic visits for monitoring

You likely don't qualify if…

you have received another cancer treatment within the last 3 weeks, or you haven't fully recovered from side effects of your last treatment
you have a history of serious autoimmune disease or currently take high-dose steroids to manage inflammation
you have an uncontrolled infection, including untreated HIV, hepatitis B, or hepatitis C
you have had a serious brain infection, seizures, or progressive neurological disease in the past year
you have received prior treatment with another PSMA-targeting therapy (other than the specific radioligand mentioned) or certain types of immunotherapy within a specific timeframe

What participation looks like

You will receive infusions of the medication (either the new treatment alone, or the new treatment combined with another drug) at regular clinic visits. The study is divided into two parts: first, doctors will test different dose levels to find what's safe, then they'll enroll more patients at those doses to see how well the treatment works. Throughout the study, you'll have blood tests, imaging scans, and office visits to monitor how you're responding and check for side effects. The exact schedule and duration will depend on which part of the study you join and how your cancer responds.

AI-generated summary from trial data · Jun 27, 2026 · Not medical advice

Testing a new immune-boosting cancer treatment alone or combined with another drug

What is this trial?

Do you qualify?

What participation looks like

Trial locations(24 sites)